Mr. Ryan Richardson: ... Pay is salary, bonuses, etc. Description. BioNTech German biotech BioNTech has appointed Ryan Richardson (pictured below, right) as chief strategy officer and managing director. Mr. Richardson brings 15 years of corporate development and finance in the healthcare and biopharmaceutical industries to BioNTech. BioNTech US Inc. (formerly Neon Therapeutics, Inc.) On May 6, ... Board have provided for a short-term incentive compensation of up to a maximum of fifty percent of the annual base salary for the years 2020, 2021 and 2022. Mr. Ryan Richardson: ... Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. BioNTech SE (/ ˌ b aɪ. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized … ɒ n ˈ t ɛ k / BYE-on-TEK; short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. Bevor er zu Biontech kam, war er als Executive Director im Global Healthcare Investment Banking Team bei J.P. Morgan in London tätig, wo er Unternehmen aus der Biotech- und Life Science Industrie bei M&A-, Eigen- und Fremdkapitalfinanzierungen beriet. Ryan Richardson brings over 15 years of experience in the finance and healthcare industries to BioNTech. Prior to joining BioNTech in 2018 as SVP Corporate Development & Strategy, Ryan was an Executive Director in the Global Healthcare Investment Banking team at J.P. Morgan in London, where he advised companies in the biotech and life sciences industry on M&A, equity and debt capital financings. Broj zaposlenih: 1.323 (2019.) The value used to calculate the number of options for Ryan Richardson increases to €280,000 for the year 2022. In his new role, he will support and contribute to the creation and implementation of BioNTech’s long-term growth strategy, in collaboration with the management team. Exercised is the value of options exercised during the fiscal year. Özlem Türeci, Sean Marett, Sierk Poetting, Ryan Richardson Djelatnost(i) Biotehnologija Proizvodi: BNT162b2 (Cjepivo protiv COVID-19) Prihod: 121.5 mil EUR (2019.) Neto dobit: 179.2 mil EUR (2019.) Mr. Ryan Richardson: Chief Strategy Officer, MD & Member of Management Board: N/A: N/A: 1980: Sylke Maas: VP of Investor Relations and Bus. Operativni prihod: 181.5 mil EUR (2019.) Prior to joining BioNTech, Ryan was an Executive Director in the Global Healthcare Investment Banking team at J.P. Morgan in London, where he advised companies in the biotech and life sciences industry on M&A, equity and debt capital financings. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. Ryan Richardson hat über 15 Jahre Erfahrung in der Finanz- und Gesundheitsbranche. See the company profile for BioNTech SE (BNTX), including business summary, industry/sector information, number of employees, corporate governance, key executives and salary information.